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Abstract
The chemokine receptor CXCR4 is activated by its unique chemokine ligand CXCL12 and
regulates many physiological and developmental processes such as hematopoietic cell traf-
ficking. CXCR4 is also one of the main co-receptors for human immunodeficiency virus
(HIV) entry. Dysfunction of the CXCL12/CXCR4 axis contributes to several human patholo-
gies, including cancer and inflammatory diseases. Consequently, inhibition of CXCR4 acti-
vation is recognized as an attractive target for therapeutic intervention. In this regard,
numerous agents modifying CXCR4 activity have been evaluated in in vitro experimental
studies and pre-clinical models. Here, we evaluated a CXCL12 competition binding assay
for its potential as a valuable initial screen for functional and competitive CXCR4 inhibitors.
In total, 11 structurally diverse compounds were included in a side-by-side comparison of in
vitro CXCR4 cell-based assays, such as CXCL12 competition binding, CXCL12-induced
calcium signaling, CXCR4 internalization, CXCL12-guided cell migration and CXCR4-spe-
cific HIV-1 replication experiments. Our data indicated that agents that inhibit CXCL12 bind-
ing, i.e. the anti-CXCR4 peptide analogs T22, T140 and TC14012 and the small molecule
antagonists AMD3100, AMD3465, AMD11070 and IT1t showed inhibitory activity with con-
sistent relative potencies in all further applied CXCR4-related assays. Accordingly, agents
exerting no or very weak receptor binding (i.e., CTCE-9908, WZ811, Me6TREN and gambo-
gic acid) showed no or very poor anti-CXCR4 inhibitory activity. Thus, CXCL12 competition
binding studies were proven to be highly valuable as an initial screening assay and indicative
for the pharmacological and functional profile of competitive CXCR4 antagonists, which will
help the design of new potent CXCR4 inhibitors.
Introduction
Human chemokines are chemotactic cytokines that are categorized based on the positioning
of well-conserved N-terminal cysteine (C) residues and classified as C, CC, CXC, CX3C
chemokines. By activating their corresponding chemokine receptors, that belong to the
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rhodopsin-like seven transmembrane G protein-coupled receptor (GPCR) family, chemokines
play a pivotal role in many processes, including hematopoiesis, immune cell trafficking and
stem and progenitor cell mobility [1]. Not surprisingly, aberrant chemokine receptor signaling
underlies many human diseases, including multiple types of cancer [2, 3].
CXC chemokine receptor 4 (CXCR4) is widely expressed on hematopoietic cells [e.g. T-
and B-lymphocytes, stem and progenitor cells (HSPCs)] as well as on endothelial and epithe-
lial cells and in diverse tissues (e.g. lung, liver, colon and heart) [4]. Upon interaction with its
unique chemokine ligand, CXC chemokine ligand 12 (CXCL12) [or stromal cell-derived fac-
tor-1 (SDF-1)], both G protein-dependent and–independent signaling pathways are acti-
vated along the CXCL12/CXCR4 axis, thereby regulating many biological responses, some of
which can have severe clinical impact [5]. Together with CC chemokine receptor 5 (CCR5),
CXCR4 is a major co-receptor facilitating human immunodeficiency virus (HIV) entry in
cluster of differentiation 4 (CD4) positive T-lymphocytes [6, 7]. More recently, CXCR4
downstream signaling pathways have been shown to contribute to cancer progression by
supporting the proliferation and survival of tumor cells and promoting tumor-related angio-
genesis and metastasis of various types of human cancer [4, 8]. CXCR4 is also associated
with several autoimmune diseases (e.g. rheumatoid arthritis) and warts, hypogammaglobuli-
nemia, immunodeficiency, myelokathexis (WHIM) syndrome is caused by activating muta-
tions in cxcr4 [9, 10]. Taken together, interference with the CXCL12/CXCR4 axis might be of
clinical significance for the treatment of various human diseases. In 2009, the first CXCR4
inhibitor [i.e. the small molecule AMD3100 (Plerixafor, Mozobil1)] was approved for clini-
cal use to support the mobilization of hematopoietic progenitor cells required for stem cell
transplantation in patients with hematological malignancies (i.e. myeloma and lymphoma)
[11, 12].
Various CXCR4-targeting compounds, including anti-CXCR4 peptides, non-peptide small
molecule antagonists, CXCL12 peptide analogs and anti-CXCR4 antibodies have so far been
evaluated in in vitro experimental studies and pre-clinical animal models to investigate their
effectiveness in inhibiting CXCR4 function [13, 14]. The variety of applied biological assays
and experimental conditions, however, makes it difficult to truly compare their binding char-
acteristics, relative potencies and mode of action (direct versus indirect mechanisms) which
might hamper their use in novel disease models and further drug design. The goal of this study
was thus to determine the binding characteristics of a selection of commercially available com-
pounds previously claimed to inhibit in vitro and/or in vivo CXCR4 signaling and function
and, in addition, to investigate to what extent these compounds are biased towards the inhibi-
tion of specific CXCR4-related pathways or functions. Therefore, all compounds were evalu-
ated side-by-side in a panel of pharmacological and functional cell-based assays. In total, 11
compounds, the peptide analogs T22 [15], T140 [16], TC14012 [17] and CTCE-9908 [18] and
the small molecules AMD3100 [12], AMD3465 [19], AMD11070 [20], IT1t [21], WZ811 [22],
Me6TREN [23] and gambogic acid [24] were included, which were all initially tested for their
ability to compete with CXCL12 at the level of receptor binding. In order to evaluate the poten-
tial bias towards a CXCR4-mediated signaling pathway or response, their activity was further
evaluated in assays measuring their effect on CXCL12-induced calcium mobilization, CXCR4
internalization, CXCL12-guided chemotaxis and CXCR4-specific (X4) HIV entry and replica-
tion. A correlation between CXCR4 binding and the relative potency of compounds to inhibit
CXCR4 signaling and function became apparent. In consequence, our data not only provide
detailed insight into the CXCR4-inhibiting activity of commercially available compounds, but
also demonstrate that applying CXCL12 competition binding studies can represent a highly
informative step in future screening strategies for the identification of novel anti-CXCR4
compounds.
Cell-based evaluation of CXCR4 inhibitors
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Materials and methods
Compounds, chemokines and antibodies
The structure of all used compounds is illustrated in S1 Fig. T22 [(Tyr5.12,Lys7)-Polyphemusin
II; MW: 2,487.0 g/mol] [15] and T140 (MW: 2,037.5 g/mol) [16] were purchased from Bachem
(Bubendorf, Switzerland). The compounds TC14012 (MW: 2,066.4 g/mol) [17], CTCE-9908
(MW: 1,927.3 g/mol) [18], IT1t (MW: 479.6 g/mol) [21] and AMD3465 Hexahydrobromide
(MW: 896.1 g/mol) [19] were obtained from Tocris (Bristol, UK). Me6TREN (MW: 230.4 g/
mol) [23] and gambogic acid (MW: 628.8 g/mol) [24] were ordered from Sigma-Aldrich
(St. Louis, MO, USA). WZ811 (MW: 290.4 g/mol) [22] was purchased from Selleckchem
(Houston, TX, USA). AMD11070 (MW: 349.5 g/mol) [20] and AMD3100 (MW: 830.5 g/mol)
[12] were kindly provided by Dr. G. Bridger (at that time at AnorMed; Langley, Canada).
Recombinant human CXCL12 was obtained from Peprotech (Rocky Hill, NJ, USA). Alexa
Fluor 647-labeled human CXCL12 (CXCL12AF647), which is synthesized by the incorporation
of the AF647 conjugate (excitation maximum: 650 nm; emission maximum: 668 nm) at the C-
terminal Lysine residue of CXCL12, was purchased from Almac (Craigavon, UK). The anti-
bodies used in this study were phycoerythrin- (PE) and allophycocyanin (APC)-labeled mouse
anti-human CXCR4 monoclonal antibodies (mAb) (clone 12G5; BD Pharmingen, San Diego,
CA, USA), PE-conjugated rat anti-human CXCR4 mAb (clone 1D9; BD Pharmingen), PE-
labeled mouse anti-human CXC chemokine receptor 7 (CXCR7) mAb (clone 10D1-J16; Bio-
Legend, San Diego, CA, USA) and PE-conjugated mouse anti-human CD4 mAb (clone SK3;
Biolegend) with the corresponding isotype controls [PE-labeled mouse IgG2a, κ isotype con-
trol mAb (clone G155-178; BD Pharmingen), APC-labeled mouse IgG2a, κ isotype control
mAb (clone G155-178; BD Pharmingen), PE-conjugated rat IgG2a, κ isotype control mAb
(clone R35-95; BD Pharmingen) and PE-labeled mouse IgG1, κ isotype control mAb (clone
MOPC-21; BD Pharmingen)].
Cell cultures
Jurkat and SUP-T1 cell lines were purchased from American type culture collection (ATCC,
Manassas, VA, USA). The MT-4 cell line was a kind gift of Dr. L. Montagnier (at that time at
the Pasteur Institute; Paris, France). CXCR4 surface expression on these cell lines was con-
firmed by flow cytometry (S2 Fig). These human T-lymphocytic cell lines were cultured in
RPMI medium (Thermo Fisher Scientific, Waltham, MA, USA) containing 10% fetal bovine
serum (FBS; Thermo Fisher Scientific) and 2 mM L-glutamine (Thermo Fisher Scientific).
Human glioblastoma U87 cells, expressing CD4 (U87.CD4) or CD4 and CXCR4 (U87.CD4.
CXCR4), were kindly provided by Dr. D. R. Littman (Skirball Institute of Biomolecular Medi-
cine; NY, USA). U87.CD4.CXCR7 cells stably expressing human CXCR7 were constructed as
described [25], from U87.CD4 cells transfected with pTEJ-8 plasmid DNA containing human
CXCR7 cDNA. All glioblastoma cell lines were cultivated in Dulbecco’s modified eagle
medium (DMEM; Thermo Fisher Scientific) supplemented with 10% FBS (Thermo Fisher Sci-
entific), 0.01 M HEPES buffer (Thermo Fisher Scientific) and antibiotics [200 μg/ml geneticin
(Thermo Fisher Scientific; CD4 selection) and 1 μg/ml puromycin (Sigma-Aldrich; CXCR4
and CXCR7 selection)]. CD4, CXCR4 and CXCR7 surface expression on these adherent cell
lines was confirmed by flow cytometry throughout all experiments (S2 Fig and data not
shown). Cell cultures were maintained at 37˚C and 5% CO2 and subcultivated every two to
three days.
Freshly isolated peripheral blood mononuclear cells (PBMCs) were isolated out of buffy
coats from healthy donors (Red Cross, Belgium). They were cultured in RPMI medium with
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10% FBS, 2 mM L-glutamine and stimulated with 2 μg/ml phytohemagglutinin (PHA; Sigma-
Aldrich) for three days before use in the HIV replication assays (see below).
Cellular cytotoxicity assay
Jurkat cells (3x105 cells per well in culture medium) were incubated with serial dilutions of
compound at room temperature (RT) for two hours. Cytotoxicity of the compounds was also
evaluated at 37˚C over a longer period of time in MT-4 cells (5x104 cells per well in culture
medium, four day incubation) and PHA-stimulated PBMCs (5x105 cells per well in culture
medium, ten day incubation) because these cell types were used in anti-HIV activity assays
which last up to ten days (see below). Each condition was tested in duplicate. Cytotoxicity was
evaluated microscopically and, in addition, cell viability was assessed using the colorimetric
CellTiter 96 AQueous One Solution Cell Proliferation Assay (Promega, Fitchburg, WI, USA),
which is based on the reduction of the tetrazolium salt MTS [3-(4,5-dimethylthiazol-2-yl)-5-
(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium] to formazan by metabolically
active cells. Absorbance at 490 nm was measured with the VersaMax ELISA Microplate Reader
(Molecular Devices, Sunnyvale, CA, USA). The cytotoxic concentration 50 (CC50) of each
compound was calculated based on the absorbance of negative (i.e. cells without compound)
and positive (i.e. only culture medium) control samples.
CXCL12AF647 binding assay
The CXCL12AF647 binding assay was performed according to Hatse et al. [26], but modified
for use in a 96-well plate format. In brief, Jurkat cells were washed twice in assay buffer
[Hank’s Balanced Salt Solution (HBSS; Thermo Fisher Scientific), 20 mM HEPES buffer
(Thermo Fisher Scientific), 0.2% bovine serum albumin (Sigma-Aldrich), pH 7.4]. 3x105 cells
(in assay buffer) were incubated with test compound (in assay buffer) at RT for 15 minutes, fol-
lowed by an additional incubation of 30 minutes with 2.9 nM CXCL12AF647. Non-treated Jur-
kat cells were incubated with the PE-labeled mouse anti-human CXCR4 mAb (clone 12G5) or
PE-conjugated mouse IgG2a, κ isotype control mAb (clone G155-178) to verify CXCR4
expression levels. Afterwards, cells were washed twice in assay buffer and subsequently fixed in
1% paraformaldehyde in Dulbecco’s phosphate buffered saline (DPBS). Samples were analyzed
with the FACSArray flow cytometer (Becton Dickinson, NJ, USA). Data were further analyzed
with the FlowJo Software (Ashland, Oregon, USA). The percentage of CXCL12AF647 binding
inhibition was calculated according to the formula [1 –(MFIX−MFINC)/(MFIPC−MFINC)] x
100, where MFIX is the mean fluorescence intensity of the compound treated sample, MFINC
the MFI of the negative control (i.e. autofluorescence of untreated and unlabeled cells) and
MFIPC the MFI of the positive control (i.e. cells exposed to CXCL12AF647 alone). The inhibitory
concentration 50 (IC50; i.e. the compound concentration that inhibits CXCL12AF647 binding
by 50%) was calculated for each compound.
Calcium mobilization assay
Intracellular calcium fluxes were measured with the FLIPR Tetra system (excitation LED
banks: 470–495 nm, emission filters: 515–575 nm; Molecular Devices). U87.CD4.CXCR4 cells
were seeded at 2x104 cells per well in gelatin-coated black-walled 96-well plates [0.1% gelatin
in DPBS, incubated at RT for two hours and washed once with DPBS] and incubated at 37˚C
and 5% CO2 overnight. Then, cells were loaded with the fluorescent calcium indicator Fluo-2
acetoxymethyl ester (AM) (4 μM; excitation: 488 nm, emission: 515 nm; Sigma-Aldrich) dis-
solved (1:1 mixture) in pluronic acid solution (20% w/v; Sigma-Aldrich) at RT in the dark for
45 minutes. In parallel, a 96-well compound plate with different concentrations of compound,
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diluted in assay buffer (see above), and a chemokine plate with CXCL12 were prepared. Fluo-2
AM loaded cells were washed with assay buffer before being incubated in the FLIPR Tetra sys-
tem at 37˚C for five minutes. At the start of the kinetic measurement, compounds were added
to the cell plate by the internal robotic system followed by an incubation period of 10 minutes
during which changes in the intracellular calcium level were continuously measured by the
FLIPR Tetra. Subsequently, CXCL12 was added (6.25 nM final concentration) and changes in
cytosolic calcium concentration were further measured simultaneously in all 96 wells. Each
condition was measured in triplicate and repeated several times as further indicated (see
Results). For each sample, the difference between the maximum and minimum percentage of
baseline (i.e. mean relative light units in each well during a fixed time interval before com-
pound or CXCL12 addition) was calculated with the ScreenWorks 4.0™ software (Molecular
Devices) and data were further processed using GraphPad Prism 7. IC50 value of each com-
pound was determined based on negative (i.e. untreated cells without CXCL12 stimulation)
and positive (i.e. untreated cells with CXCL12 stimulation) control samples.
Internalization assay
T-lymphoblastic SUP-T1 cells were washed twice in DPBS containing 2% FBS. Afterwards,
cells were first incubated with the PE-labeled rat anti-human CXCR4 mAb (clone 1D9; 2 μg/
ml in DPBS/2% FBS; BD Pharmingen) on ice for 45 minutes. To assess aspecific binding, cells
were also stained with the PE-conjugated rat IgG2a, κ isotype control mAb (clone R35-95;
2 μg/ml in DPBS/2% FBS; BD Pharmingen). SUP-T1 cells were subsequently washed once
with ice cold DPBS and twice with ice cold assay buffer (see above) before being treated with
test compound on ice for 15 minutes. Next, cells were stimulated with 6.25 nM CXCL12 at
37˚C for 30 minutes to induce receptor internalization and transferred to an acidic DPBS solu-
tion (pH 2), to allow cleavage of all remaining, non-internalized cell surface CXCR4 receptors.
To evaluate the potential agonistic activity of the compounds, compound-treated samples
were incubated at 37˚C in the absence of CXCL12. Samples were immediately analyzed with
the FACSCalibur flow cytometer (Becton Dickinson) whereby the measured fluorescence cor-
responds to the amount of internalized CXCR4 receptors. Data were further analyzed with the
FlowJo software. The IC50 (i.e. the compound concentration that inhibits the CXCL12-induced
CXCR4 internalization by 50%) was calculated for each compound based on the MFI of the
negative (i.e. cells without compound and not stimulated with CXCL12) and positive (i.e. cells
without compound and stimulated with CXCL12) control.
Chemotaxis assay
Jurkat cells were washed twice in assay buffer (see above), dispensed into a 96-well plate (5x105
cells per well) containing serial dilutions of compounds (in assay buffer) and incubated at RT
in the dark for 10 minutes. Meanwhile, 6.25 nM CXCL12 (in assay buffer) was added to the
bottom wells of a 96-well chemotaxis plate (Corning, NY, USA). Suspensions of 1.87x104 cells
were transferred to the chemotaxis insert plate. Cells were allowed to migrate in response to
CXCL12 at 37˚C and 5% CO2 for two hours. After removal of the insert plate, migrated cells
were centrifuged and resuspended in DPBS containing flow cytometry cell counting beads
(SPHERO AccuCount Fluorescent Particles; Gentaur, London, UK). Both migrated cells and
particles were counted by flow cytometry (FACSCanto II; Becton Dickinson). Each compound
concentration was tested in triplicate. Data were analyzed using the FlowJo software and the
total number of migrated cells was calculated, according to the counted and total number of
beads present in the sample. IC50 values of the compounds were calculated relative to the total
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migrated cells in the negative (untreated, spontaneously migrated cells) and positive (untreated,
cells migrated towards CXCL12) control samples.
Anti-HIV activity assays
The anti-HIV replication assays in MT-4 cells and PHA-stimulated PBMCs have been described
previously [27]. The HIV-1 T-tropic molecular clone NL4-3 (X4) was obtained from the
National Institute of Allergy and Infectious Disease (NIAID) AIDS reagent program (Bethesda,
MD, USA). Briefly, 5x104 MT-4 cells (in cell culture medium) were treated with different con-
centrations of compound at 37˚C for 30 minutes. Afterwards, a 50% tissue culture infectious
dose of the NL4-3 viral stock was added to the cell-compound mixtures. Four days post infec-
tion, the cytopathic effect was evaluated microscopically and cell viability was assessed with the
MTS method, as described above.
PHA-stimulated PBMCs at 5x105 cells per sample, pre-incubated with test compounds dis-
solved in cell culture medium containing IL-2 (2 ng/ml; R&D systems Europe, Abingdon,
UK), were infected with NL4-3. After three days, fresh culture medium with IL-2 was added.
Ten days post infection cell supernatant was collected for HIV-1 p24 core antigen enzyme-
linked immunosorbent assay (ELISA; Perkin Elmer, Boston, MA, USA) according to the man-
ufacturer’s protocol.
In the antiviral assays, each condition was tested in duplicate. Based on the absorbance
measured in the negative (i.e. untreated and uninfected cells) and positive (i.e. untreated virus-
infected cells) control samples, the IC50, defined as the test compound concentration that
inhibits HIV-induced cell death by 50%, was calculated.
Results
Cytotoxicity of the investigated compounds
In total, 11 compounds were included in this study: the CXCR4 peptide analogs T22 [15] and
its derivatives (T140 [16] and TC14012 [17]), the CXCL12 peptide analog CTCE-9908 [18]
and the non-peptide small molecule CXCR4 antagonists AMD3100 [12] and derivatives
(AMD3465 [19], AMD11070 [20]), IT1t [21], WZ811 [22], Me6TREN [23] and gambogic acid
[24] (S1 Fig). To determine the maximum compound concentration to be used in our panel of
screening assays, the cellular cytotoxicity of all compounds was first evaluated. Based upon
microscopical evaluation of Jurkat cells and quantification of cell viability using MTS, the cyto-
toxic concentration 50 (i.e. CC50; the concentration that reduces cell viability by 50%) was
determined. CC50 values were 100 μM for all compounds, with exception of gambogic acid
for which a CC50 value of 10 μM was obtained. In consequence, the potential anti-CXCR4
activity of gambogic acid was further assayed at concentrations up to 10 μM whereas for all
other compounds 100 μM was used as the highest concentration. Similar results were obtained
in MT-4 cells and PHA-stimulated PBMCs after four and ten days incubation with com-
pounds, respectively. None of the compounds showed remarkable cytotoxicity in these cell
types. Only gambogic acid was toxic in both MT-4 cells and PHA-stimulated PBMCs at low
micromolar concentrations (CC50 ~ 300 nM).
Effect of CXCR4 compounds on CXCL12 binding to CXCR4
We investigated to what extent the different classes of agents were able to compete for receptor
binding with CXCL12, the endogenous CXCR4 ligand. To ensure binding specificity, these
experiments were performed using Jurkat cells endogenously expressing CXCR4, but not
CXCR7, which shares CXCL12 as a common ligand (S2 Fig). Jurkat cells were pretreated with
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serial dilutions of compound and thereafter incubated with CXCL12AF647. The fluorescent sig-
nal of specific CXCL12AF647 binding was then quantified by flow cytometry. All compounds
inhibited the CXCL12/CXCR4 interaction, albeit with different potencies (Fig 1; S1 Table).
The peptide analogs T22, T140 and TC14012 and the small molecule antagonists AMD3100,
AMD3465, AMD11070 and IT1t showed very potent and dose-dependent inhibition of
the CXCL12/CXCR4 interaction with IC50 values in the low nanomolar range [IC50s:
0.079 ± 0.034 nM (T22), 0.12 ± 0.025 nM (T140), 0.11 ± 0.0094 nM (TC14012), 12.0 ± 1.1 nM
(AMD3100), 2.1 ± 0.24 nM (AMD3465), 0.67 ± 0.10 nM (AMD11070), 2.1 ± 0.37 nM (IT1t)]
(Fig 1A and 1B). In contrast, CTCE-9908, WZ811, Me6TREN and gambogic acid only weakly
inhibited CXCL12 receptor binding with relatively high IC50 values in the micromolar range
[IC50s: 19,145 ± 2,380 nM (CTCE-9908); >100,000 nM (WZ811); 51,934 ± 8,952 nM (Me6T-
REN); 7,063 ± 532 nM (gambogic acid)] (Fig 1A and 1C). In addition, all compounds were
tested for their ability to inhibit CXCL12 binding on CXCR7-transfected U87 cells (U87.CD4.
CXCR7) whereby only AMD11070 [28] and TC14012 [29] reduced CXCL12 binding on
CXCR7 in the lower micromolar range, while all other compounds did not or only very weakly
inhibit CXCL12/CXCR7 interaction (data not shown).
Effect of CXCR4 compounds on CXCL12-induced intracellular calcium
signaling
CXCL12 binding to the receptor will result in receptor activation. The transient increase in
cytosolic calcium concentration is an important signaling pathway that is activated upon
CXCR4 stimulation. The calcium mobilization assay allowed to evaluate both the potential
agonistic (in absence of CXCL12) as well as the antagonistic activity (i.e. the potency to inhibit
the CXCL12-induced calcium mobilization) of the compounds in real time using the FLIPR
Tetra system (Fig 2; S3 Fig; S1 Table). U87.CD4.CXCR4 cells were first loaded with the fluores-
cent calcium indicator Fluo-2 AM. Treatment of cells with CXCL12 alone elicited a dose-
dependent increase of the calcium concentration (EC50 = 1.6 nM, EC90 = 10.9 nM). This
CXCL12-induced calcium flux was CXCR4 specific, since CXCL12 did not elicit a calcium flux
in U87.CD4 cells (data not shown). The effect of the compounds on the intracellular calcium
mobilization was determined by pre-incubating the cells with compound (agonistic activity;
S3 Fig) and subsequently stimulating them with 6.25 nM CXCL12 (antagonistic activity; Fig
2). CTCE-9908 showed very weak agonist activity when tested at 100 μM (S3 Fig), and this
activity was lost when tested at 20 μM. None of the other compounds displayed agonistic activ-
ity by themselves at the concentrations tested (S3 Fig). AMD11070 showed antagonistic activ-
ity as it dose-dependently inhibited the CXCL12-induced intracellular calcium flux (IC50:
12.3 ± 1.7 nM) (Fig 2A). This calcium flux was also inhibited by the peptide analogs T22, T140
and TC14012 and the low molecular weight antagonists AMD3100, AMD3465 and IT1t with
the following IC50s: 9.3 ± 3.2 nM; 1.2 ± 0.17 nM; 0.95 ± 0.18 nM; 723.0 ± 99.1 nM; 53.4 ± 24.3
nM and 23.1 ± 4.6 nM, respectively (Fig 2B and 2C). Gambogic acid inhibited the calcium flux
to a somewhat lesser extent (IC50: 4,371 ± 672 nM) (Fig 2D). 100 μM of CTCE-9908, WZ811
and Me6TREN did not affect the calcium flux evoked by CXCL12 (IC50s>100,000 nM) (Fig
2B and 2D).
Inhibition of CXCL12-induced CXCR4 receptor internalization
A feature of CXCR4, shared with many other GPCRs, is its internalization following agonist
binding, also known as receptor endocytosis. To evaluate the potential inhibitory effect of the
compounds on CXCR4 endocytosis, CXCR4 receptors endogenously expressed on SUP-T1
cells were first stained with a PE-labeled rat anti-human CXCR4 mAb targeting the receptor’s
Cell-based evaluation of CXCR4 inhibitors
PLOS ONE | https://doi.org/10.1371/journal.pone.0176057 April 14, 2017 7 / 18
N-terminus (clone 1D9) and subsequently incubated with compound. Afterwards, samples
were stimulated with CXCL12 to induce the sequestration of CXCR4 and the degree of recep-
tor internalization was quantified by flow cytometry (Fig 3A). Control experiments in which
stained SUP-T1 cells were stimulated with CXCL12 in absence of compound showed strong
cellular staining (Fig 3A), thus indicating that CXCL12 did not compete with the labeled
CXCR4 mAb for CXCR4 binding. In addition, when SUP-T1 cells were incubated with com-
pound for thirty minutes at 4˚C, and afterwards stained with the CXCR4 mAb (1D9) for thirty
minutes at 4˚C, no displacement (i.e. decrease in mAb binding) of the CXCR4 mAb was
observed by flow cytometry (data not shown). This demonstrates that also the compounds
Fig 1. Interference with CXCL12/CXCR4 interaction by the tested compounds. (A), (B) and (C):
Inhibition of the CXCL12/CXCR4 interaction by (A) the peptide analogs T22, T140, TC14012 and CTCE-9908
and the small molecules (B) AMD3100, AMD3465, AMD11070, IT1t and (C) WZ811, Me6TREN and
gambogic acid. Jurkat cells were incubated with 2.9 nM CXCL12AF647 in the presence of different
concentrations of compound. Data are represented as % inhibition of maximal CXCL12 binding to CXCR4.
Mean ± SEM of three or four independent experiments is shown.
https://doi.org/10.1371/journal.pone.0176057.g001
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themselves were unable to reduce mAb (1D9) binding to CXCR4. In consequence, reduced
cellular staining in our assay reflects the inhibitory effects of compounds on receptor internali-
zation and not simply displacement of the CXCR4 mAb.
No inhibition of CXCR4 internalization was observed when SUP-T1 cells were treated with
CTCE-9908, WZ811, Me6TREN and gambogic acid at the tested concentrations (WZ811,
Me6TREN and CTCE-9908: IC50s >100,000 nM; gambogic acid: IC50 >10,000 nM) (Fig 3B
and 3D; S1 Table). All other compounds inhibited the CXCL12-induced CXCR4 internaliza-
tion in a dose-dependent manner. T22 and derivatives were more potent inhibitors of CXCR4
internalization compared to the low molecular weight compounds AMD3100, AMD3465,
AMD11070 and IT1t (Fig 3B and 3C). The following IC50s were obtained: 10.2 ± 1.5 nM
(T22); 2.2 ± 0.4 nM (T140); 1.9 ± 0.2 nM (TC14012); 148.0 ± 36.0 nM (AMD3100); 67.3 ± 11.3
nM (AMD3465); 70.5 ± 13.1 nM (AMD11070) and 105.7 ± 12.3 nM (IT1t) (S1 Table). Of note,
in absence of CXCL12, none of the tested compounds induced CXCR4 internalization at the
highest concentration tested (i.e. 50 μM for T22, T140, TC14012, AMD3100, AMD3465,
AMD11070 and IT1t; 100 μM for CTCE-9908, WZ811 and Me6TREN; 10 μM for gambogic
acid), demonstrating the absence of an agonistic effect of the compounds themselves (data not
shown).
Antagonistic effects on CXCL12-directed migration of Jurkat cells
The directional migration of leukocytes and stem and progenitor cells is a key function of che-
mokines. CXCL12 binding to CXCR4-expressing cells will evoke a chemotactic biological
Fig 2. Antagonistic effect of compounds on CXCL12-induced calcium signaling in U87.CD4.CXCR4
cells. Fluo-2 AM loaded cells were treated with serial dilutions of compound and subsequently stimulated with
6.25 nM CXCL12. Fluorescence changes were measured over time in all wells simultaneously. (A): The
inhibitory effect of different concentrations of AMD11070 on CXCL12-induced calcium release is shown. The
red and blue line represent the negative (untreated, without CXCL12 stimulation) and positive (untreated,
CXCL12 stimulation) control, respectively. Calcium fluxes are represented as % of baseline (i.e. mean relative
light units in each well during a fixed time interval before CXCL12 addition). One representative experiment
out of three is shown with each data point corresponding to the mean fluorescence of three to six replicates.
(B), (C) and (D): Inhibitory effect of (B) T22, T140, TC14012, CTCE-9908, (C) AMD3100, AMD3465,
AMD11070, IT1t, (D) WZ811, Me6TREN and gambogic acid on CXCL12-induced calcium flux. Data are
represented as % inhibition of CXCL12-induced calcium mobilization relative to the positive and negative
control. Mean ± SEM of three independent experiments is shown.
https://doi.org/10.1371/journal.pone.0176057.g002
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effect on these cells. The capacity of the compounds to inhibit the chemotaxis of Jurkat cells
was determined using transwell migration assays (Fig 4; S1 Table). CXCL12 at 6.25 nM elicited
a strong chemotactic response on CXCR4-positive Jurkat cells (positive control) compared to
buffer-treated cells (negative control). WZ811 and Me6TREN, tested at 100 μM, did not
inhibit the migration of Jurkat cells (IC50s >100,000 nM) (Fig 4C). CTCE-9908 and gambogic
acid were very weak inhibitors of migration (with the following IC50s,: 23,593 ± 1,711 nM and
1,888 ± 353 nM, respectively), while a potent and dose-dependent inhibitory effect of chemo-
taxis by IT1t, AMD3100 and T22 and its derivatives was observed [IC50s: 470.2 ± 16.5 nM
(T22); 73.7 ± 26.0 nM (T140); 58.3 ± 22.3 nM (TC14012); 1,431 ± 485 nM (AMD3100);
116.0 ± 15.2 nM (AMD3465); 74.9 ± 17.7 nM (AMD11070) and 79.1 ± 9.6 nM (IT1t)] (Fig 4).
The chemotactic response of Jurkat cells was most effectively inhibited by TC14012. A total
inhibition of migration was obtained when cells were pretreated with TC14012 at concentra-
tions as low as 200 nM (Fig 4A).
Evaluation of the anti-HIV activity against X4 HIV-1 NL4-3
A key role for CXCR4 is its involvement as a co-receptor in HIV viral entry [6]. The antiviral
activity of the compounds against the laboratory X4-tropic HIV-1 strain NL4-3 was deter-
mined in MT-4 cells and PHA-stimulated PBMCs. Cells were pretreated with non-toxic com-
pound concentrations and subsequently infected with HIV-1 NL4-3. Viral replication was
quantified four days (MT-4 cells; MTS assay) or ten days (PHA-stimulated PBMCs; p24 Ag
Fig 3. Inhibitory effect of CXCR4 compounds on CXCL12-induced receptor endocytosis in SUP-T1
cells. SUP-T1 cells were stained with a mAb targeting the N-terminus of CXCR4 (clone 1D9) and then treated
with different concentrations of compound. CXCR4 internalization was induced by stimulating samples with
CXCL12 at 37˚C and quantified by flow cytometry. (A): Flow cytometric analysis of the negative (untreated, no
CXCL12 stimulation; red histogram) and positive (untreated, CXCL12 stimulation; dark blue histogram)
control and TC14012-treated samples (50 nM to 0.5 nM; light blue, green and orange histogram,
respectively). (B), (C) and (D): Inhibitory effect of (B) T22, T140, TC14012, CTCE-9908, (C) AMD3100,
AMD3465, AMD11070, IT1t, (D) WZ811, Me6TREN and gambogic acid on CXCR4 endocytosis. Data are
represented as % of CXCR4 internalization relative to the positive and negative control. Mean ± SEM of at
least two independent experiments is shown.
https://doi.org/10.1371/journal.pone.0176057.g003
Cell-based evaluation of CXCR4 inhibitors
PLOS ONE | https://doi.org/10.1371/journal.pone.0176057 April 14, 2017 10 / 18
ELISA) post infection. Similar antiviral activity of the compounds was observed in both cell
types. CTCE-9908, WZ811, Me6TREN and gambogic acid were not or very weakly active
against HIV-1 replication when tested at nontoxic concentrations. TC14012 was an improved
inhibitor of viral replication compared to the two other polyphemusin II-derived peptides
T22 and T140. The antiviral potency of the AMD inhibitors AMD3100, AMD3465 and
AMD11070 was comparable in both MT-4 cells and PHA-stimulated PBMCs (Table 1).
Taken together, our results highlight a correlation between the activity of the compounds
to inhibit CXCL12 receptor binding on the one hand, and calcium mobilization (Fig 5A),
CXCR4 receptor internalization (Fig 5B), cell migration (Fig 5C) and HIV entry (Fig 5D) on
the other hand. This indicates that CXCL12 binding experiments are very informative as an
initial screening assay to evaluate the activity of competitive CXCR4 inhibitors.
Fig 4. CXCL12-guided migration of Jurkat cells is inhibited by CXCR4-interacting compounds. (A), (B)
and (C): Effect of (A) T22, T140, TC14012, CTCE-9908, (B) AMD3100, AMD3465, AMD11070, IT1t, (C)
WZ811, Me6TREN and gambogic acid on chemotaxis of CXCR4-positive Jurkat cells. After compound
treatment, cells were allowed to migrate towards 6.25 nM CXCL12, present in the lower compartment of the
insert, for two hours. The migrated cells were counted by flow cytometry. Data are represented as % inhibition
of migration relative to the negative and positive control (spontaneously migrated cells and cells migrated
towards CXCL12, respectively). ± SEM of two to three independent experiments, each performed in triplicate.
https://doi.org/10.1371/journal.pone.0176057.g004
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Discussion
Given the early discovery that chemokine receptor CXCR4 facilitates HIV-1 entry in CD4-po-
sitive T-lymphocytes, this receptor was initially studied as a candidate drug target for anti-HIV
therapy [6, 14]. This led to the discovery of several CXCR4-targeting compounds capable of
Table 1. Anti-HIV-1 (X4) activity of CXCR4 compounds evaluated in CD4-positive MT-4 cells and PHA-stimulated PBMCs.
IC50a (nM)
MT-4 cells PHA-stimulated PBMCs
T22 96.0 ± 10.5 64.0 ± 12.1
T140 13.5 ± 7.1 10.4 ± 4.8
TC14012 7.2 ± 2.3 9.3 ± 4.0
CTCE-9908 16,499 ± 1,985 59,568 ± 11,142
AMD3100 11.8 ± 3.4 14.9 ± 3.2
AMD3465 21.8 ± 10.1 27.2 ± 8.7
AMD11070 11.9 ± 4.6 26.4 ± 6.1
IT1t 14.2 ± 5.3 19.0 ± 2.3
WZ811 >100,000 38,234 ± 3,794
Me6TREN >100,000 >100,000
gambogic acid >376.1 >225.2
a Compound concentration required to inhibit HIV-1 (X4) NL4-3 replication by 50%. Mean IC50 ± SEM are represented of four (MT-4 cells) or two to four
(PHA-stimulated PBMCs) separate experiments.
https://doi.org/10.1371/journal.pone.0176057.t001
Fig 5. Correlation between the CXCR4 binding characteristics of the compounds and their potency to
inhibit CXCL12/CXCR4 signaling and function. (A), (B), (C) and (D): Correlation between the IC50 value of
the compounds for CXCL12 receptor binding inhibition and inhibition of (A) CXCL12-induced calcium
signaling (p<0.0001; R2 = 0.95), (B) CXCR4 internalization (p<0.0001; R2 = 0.96), (C) chemotaxis (p<0.0001;
R2 = 0.84) and (D) HIV viral entry (in MT-4 cells) (p = 0.0002; R2 = 0.81). The maximum test concentration of
CTCE-9908, WZ811, Me6TREN and gambogic acid is represented when no activity was detected.
Correlations were calculated in Graphpad using the Pearson correlation test (p-values < 0.05 were
considered as statistical significant).
https://doi.org/10.1371/journal.pone.0176057.g005
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inhibiting HIV infection in CD4-positive T-lymphocytes, including the cyclams, polyphemu-
sin II and analogs derived thereof. Due to growing evidence that supports an important role
for CXCR4 in tumor progression, stem and progenitor cell mobility and autoimmune diseases,
CXCR4 gained broad attention as an attractive target for therapeutic intervention in various
disease areas. Multiple strategies for inhibiting CXCR4 function, including small molecule
antagonists, peptide inhibitors, neutralizing antibodies and nanobodies have been developed
and evaluated in in vitro assays and in vivo pre-clinical models [13]. Due to the divergent sig-
naling pathways evoked upon CXCR4 stimulation, a multitude of screening and functional
assays can be envisaged for drug discovery. To our knowledge, this study presents for the first
time a side-by-side comparative evaluation of commercially available CXCR4-targeting agents
(S1 Fig) in diverse cell-based assays, which until now has been hampered by the divergence of
experimental conditions used in previous studies.
Our work suggests that profiling the compound’s binding characteristics via competition
binding studies with the orthosteric ligand (i.e. CXCL12) is predictive for its general pharma-
cological and functional anti-CXCR4 activity. Hence, evaluating the binding characteristics of
novel compounds compared to a given reference compound might be a valuable initial screen-
ing strategy guiding novel drug discovery workflows in order to evaluate the potency of com-
petitive CXCR4 antagonists. Until now, it has also been unclear if the compounds included in
this study show a bias towards the inhibition of a particular pathway or functional response.
Here, we demonstrate that this is likely not the case. A compound shown to physically interact
with the ligand binding pocket of CXCR4 effectively inhibited the response in all signal trans-
duction and functional receptor assays tested with consistent relative potencies, while com-
pounds that did not interfere with agonist binding showed no or only very limited effect (Fig
5). Biased GPCR ligands, including antagonists that preferentially inhibit one functional or sig-
naling pathway over the other have been described for other GPCRs [30, 31] and raise general
interest since they might evoke less side effects in clinical settings [32]. Our data, however,
indicate that compounds commonly used to interrupt CXCL12/CXCR4 interaction display no
bias in activity when tested in functional assays relevant for CXCR4. Obviously, this does not
exclude that biased CXCR4 antagonists, or biased agonists that stabilize particular active recep-
tor conformations while blocking others, might be discovered in the future.
Several studies have previously reported in vivo inhibitory activity of Me6TREN [23] and
CTCE-9908 [18] without demonstration of a direct interaction with the CXCR4 receptor. Our
data confirm this lack of a direct effect on CXCR4 and thus imply that CXCR4 function can
still be downregulated in vivo without the requirement for a direct receptor-compound inter-
action. It has been suggested that the small molecule Me6TREN mobilizes in vivo HSPCs by
upregulation of matrix metallopeptidase-9 (MMP-9), which subsequently decreases CXCL12
levels in the bone marrow, leading to reduced CXCL12/CXCR4 interaction and the egress of
HSPCs into circulation [23]. In the same study, low micromolar amounts of Me6TREN dose-
dependently inhibited CXCL12-directed in vitro migration of Jurkat cells. Me6TREN also
increased CXCL12-induced phosphoAKT, phosphoERK and phosphop38 protein levels,
although the cAMP pathway was not significantly activated [23]. We did observe neither an
inhibitory effect, nor a stimulatory effect of Me6TREN on CXCL12 receptor binding, chemo-
taxis of Jurkat cells and CXCL12-induced intracellular calcium release (Figs 1C, 2D and 4C).
Our findings thus support the idea that Me6TREN most likely inhibits CXCR4 function in
vivo via an indirect pathway, for instance by upregulating the levels of MMP-9. The peptide
analog of CXCL12, CTCE-9908, exhibits anti-tumoral effects in in vivo tumor models, includ-
ing breast, prostate and esophageal cancer, by inhibiting CXCL12-induced primary tumor
growth and metastasis [33–36]. Pretreatment of osteosarcoma cells with CTCE-9908 also
affects several stages of tumor development in vitro, such as adhesion, migration, invasion and
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growth [34]. In addition, a study by Drenckhan et al. showed that CTCE-9908 exhibits anti-
proliferative and -migratory effects on esophageal cells [33]. The anti-tumoral effects of
CTCE-9908 observed in the above mentioned studies were obtained after long-term (24
hours) treatment with relatively high concentrations of CTCE-9908 (approximately 50 μM),
which might explain why we did not observe inhibition of Jurkat cell migration by CTCE-9908
(Fig 4A). Indeed, our experimental design in which all compounds are compared side-by-side
under standardized conditions shows that CTCE-9908 likely has rather poor direct anti-
CXCR4 activity, if any activity at all. Further studies should be pursued to unravel the mecha-
nism of action of CTCE-9908.
Using computational docking gambogic acid has previously been predicted to physically
interact with CXCR4 and this binding is comparable to the binding mode of AMD3100.
Experimental data to support this prediction, however, were not included [24]. We demon-
strate that gambogic acid competes with CXCL12 for CXCR4 binding, although with relatively
low potency (IC50 in the micromolar range) when compared to AMD3100. Apart from a pre-
sumed direct effect on CXCR4, an indirect inhibitory effect of gambogic acid, driven by its
capacity to suppress NF-кB binding to the CXCR4 promoter, was demonstrated. This leads to
downregulation of CXCR4 mRNA and protein levels, detectable as early as 12 hours post treat-
ment. Receptor downregulation was correlated with reduced CXCL12-mediated invasion of
multiple myeloma cells after 24 hours incubation with gambogic acid [24]. In our study, we
found that gambogic acid only weakly inhibited CXCL12-induced calcium signaling and che-
motaxis (Figs 2D and 4C). Given the short incubation time of these assays (up to two hours for
chemotaxis), this mild inhibitory effect is likely not caused by the decrease in CXCR4 mRNA
expression, but rather reflects the weak binding to CXCR4. Taken together, it appears that
gambogic acid might modulate CXCR4 function by both direct and indirect mechanisms.
However, despite the anti-CXCR4 activity observed for gambogic acid, it is important to note
its high cellular cytotoxicity when tested in two different cell lines (i.e. Jurkat and MT-4 cells)
as well as primary cells (i.e. PBMCs) rendering it a less suitable molecule for use in some pre-
clinical disease models.
WZ811, sharing common structural features with AMD3100, was initially described by
Zhan et al. [22]. Despite their structural similarity, the binding mode of WZ811 is quite differ-
ent from that of AMD3100 [37]. WZ811 potently inhibits binding of TN14003 [22], a peptide
CXCR4 antagonist [17], but it has been unclear whether WZ811 also directly effects CXCL12
receptor binding. In our experiments WZ811 was unable, even at high concentration, to
inhibit the interaction between CXCL12 and CXCR4 on both Jurkat (Fig 1C) as well as
SUP-T1 cells (data not shown). Additional binding experiments using labeled CXCR4 mono-
clonal antibodies targeting distinct receptor regions [i.e. 12G5 clone (targeting the second
extracellular loop) and 1D9 clone (targeting the N-terminal receptor portion)] were per-
formed, but also indicated that WZ811 was unable to reduce mAb binding (data not shown).
WZ811 was inactive in all of our pharmacological and functional CXCR4 assays in contrast to
previous studies that showed inhibition of CXCL12-induced migration/invasion with even
greater potency than AMD3100 [22, 38]. Overall, the lack of inhibitory activity of WZ811 in
our diverse set of experiments suggests that WZ811 is not, or at least a very weak CXCR4
inhibitor.
The first generation peptide inhibitor T22 and small molecule antagonist AMD3100 were
discovered as potent CXCR4 inhibitors of HIV infection [15, 39]. In order to improve their
anti-HIV activity and pharmacokinetic properties, several derivatives and novel agents were
designed (e.g. T140, TC14012, AMD3465, AMD11070 and IT1t) [14, 21]. All of them are
potent CXCR4 inhibitors of HIV-1 replication (Table 1). From our comparative study, we con-
clude that the polyphemusin II-derived CXCR4 peptides exhibit a better activity profile than
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the tested small molecules, supporting previously published data (Table 1 and S1 Table) [26,
40]. The discrepancy in binding and inhibitory potency between both classes of compounds (i.
e. peptide analogs vs small molecule antagonists) are not clearly understood, but could in part
be explained by differences in crucial interaction residues in the receptor’s ligand binding cav-
ity. For instance, crystallization studies of CXCR4 demonstrated that IT1t occupies only part
of the binding pocket, whereas the peptide CVX15 (a T140 analog) fills most of the binding
pocket volume. Moreover, CVX15 might induce significant conformational changes in the
receptor dimer, which could potentially result in negative binding cooperativity of CXCR4
[41].
In summary, we evaluated the binding characteristics and relative potencies of several clas-
ses of CXCR4 inhibitors, previously described to inhibit CXCR4 function in vitro and/or in
vivo, in a panel of pharmacological and functional receptor assays. Side-by-side comparison
indicated that CTCE-9908, WZ811, Me6TREN and gambogic acid are not, or at least very
weak, direct CXCR4 inhibitors, although some of them might modulate CXCR4 function in
vivo by indirect mechanisms. On the other hand, T22, T140, TC14012, AMD3100, AMD3465,
AMD11070 and IT1t demonstrated potent anti-CXCR4 activity, driven by the competition
with CXCL12 for receptor occupancy. This makes these latter compounds the best candidate
molecules for further evaluation of the role of CXCR4 in (pre-)clinical disease models and
drug design.
Supporting information
S1 Fig. Amino acid sequence of the CXCR4-targeting peptides (A) T22, T140, TC14012
and CTCE-9908 and structures of the chemical compounds (B) AMD3100, AMD3465,
AMD11070, IT1t and (C) WZ811, Me6TREN, gambogic acid. Disulfide bridges are indi-
cated with a black line.
(TIF)
S2 Fig. CXCR4, CXCR7 and CD4 expression on (A) Jurkat, (B) SUP-T1, (C) MT-4 and (D)
U87.CD4.CXCR4 cells. (A), (B) and (C): Cell surface CXCR4 and CXCR7 expression was
quantified by flow cytometry. Red and blue histogram represent the isotype control staining
and the CXCR4 or CXCR7 cell surface expression, respectively. (D): U87.CD4.CXCR4 cells
were stained with mAbs targeting CXCR4, CXCR7, CD4 (blue histogram) and the correspond-
ing isotype controls (red histograms). Cell surface expression of the receptors was continu-
ously monitored throughout all experiments. Data from one representative experiment are
shown.
(TIF)
S3 Fig. Agonistic activity of the compounds on intracellular calcium flux in U87.CD4.
CXCR4 cells. Fluo-2 AM loaded U87.CD4.CXCR4 cells were incubated with test compound
for 10 minutes during which changes in intracellular calcium concentration were measured to
evaluate the agonistic activity of the compounds in the absence of CXCL12 (time interval:
0–600 seconds). Afterwards, the inhibitory effect of the compounds on the CXCL12-induced
calcium flux was determined (time interval: 600–830 seconds). Calcium fluxes are represented
as % of baseline (i.e. mean relative light units in each well during a fixed time interval before
compound and CXCL12 addition. For each compound the highest tested concentration is
shown: (A) T22, (B) T140, (C) TC14012, (F) AMD3465, (G) AMD11070 and (H) IT1t at 1,000
nM; (E) AMD3100 at 25,000 nM; (K) gambogic acid at 10,000 nM; (D) CTCE-9908, (I)
WZ811 and (J) Me6TREN at 100,000 nM. The red and blue line represent the negative
(untreated, without CXCL12 stimulation) and positive (untreated, CXCL12 stimulation)
Cell-based evaluation of CXCR4 inhibitors
PLOS ONE | https://doi.org/10.1371/journal.pone.0176057 April 14, 2017 15 / 18
control, respectively.
(TIF)
S1 Table. Antagonistic activity of CXCR4 inhibitors on CXCL12/CXCR4 binding interac-
tion, CXCL12-induced calcium signaling, chemotaxis and CXCR4 receptor internaliza-
tion.
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